Literature DB >> 19549239

Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.

J Boer1, G B E Jemec.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by abscess formation localized to apocrine sweat gland-bearing skin. The most important factor in patients' overall assessment of disease severity is pain. The duration of abscesses takes days to weeks and are always painful. AIM: To assess the efficacy of self-treatment with topical 15% resorcinol in an open study.
METHODS: The case notes of 12 women with stage 1 or 2 HS treated with topical resorcinol and followed up for at least 1 year were reviewed. The patients rated the efficacy of treatment on global maximum pain of nodules and abscesses on a visual analogue scale (VAS) and by self-report of the mean duration (days) of a painful lesion.
RESULTS: All patients experienced a significant decrease in pain as assessed by VAS and reported a reduction in mean duration of the painful abscesses.
CONCLUSIONS: Topical treatment with 15% resorcinol reduced pain from painful nodules in all patients with HS. Further trials are warranted to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549239     DOI: 10.1111/j.1365-2230.2009.03377.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  15 in total

Review 1.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

Review 2.  [Drug therapy of acne inversa].

Authors:  S Schneider-Burrus; E Arpa; C Kors; T Stavermann; R Sabat; G Kokolakis
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 3.  Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice.

Authors:  Lauren A V Orenstein; Tien V Nguyen; Giovanni Damiani; Christopher Sayed; Gregor B E Jemec; Iltefat Hamzavi
Journal:  Dermatology       Date:  2020-05-14       Impact factor: 5.366

Review 4.  Hidradenitis suppurativa in children and adolescents: a review of treatment options.

Authors:  Peter Riis Mikkelsen; Gregor B E Jemec
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

Review 5.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

Review 6.  What is hidradenitis suppurativa?

Authors:  Erika Yue Lee; Raed Alhusayen; Perla Lansang; Neil Shear; Jensen Yeung
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

Review 7.  [Topical and novel device-based therapies for mild hidradenitis suppurativa].

Authors:  G Nikolakis; E von Stebut
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

Review 8. 

Authors:  Erika Yue Lee; Raed Alhusayen; Perla Lansang; Neil Shear; Jensen Yeung
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

Review 9.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

10.  Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.

Authors:  Elisa Molinelli; Valerio Brisigotti; Oriana Simonetti; Claudia Sapigni; Giovanni Marco D'Agostino; Giulio Rizzetto; Alfredo Giacchetti; Annamaria Offidani
Journal:  Dermatol Ther       Date:  2022-03-18       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.